Rectosigmoid resection during Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer: morbidity of gynecologic oncology vs. colorectal team

被引:9
作者
Tozzi, Roberto [1 ,2 ]
Valenti, Gaetano [1 ]
Vinti, Daniele [1 ]
Campanile, Riccardo Garruto [1 ]
Cristaldi, Massimo [3 ]
Ferrari, Federico [1 ]
机构
[1] Univ Oxford, Churchill Hosp, Dept Gynaecol Oncol, Oxford, England
[2] Univ Oxford, Nuffield Dept Women & Reprod Hlth, Oxford, England
[3] Harley St Med Ctr, Dept Colorectal Surg, Abu Dhabi, U Arab Emirates
关键词
Ovarian Cancer; Surgery; Morbidity; EN-BLOC RESECTION; CYTOREDUCTIVE SURGERY; NEOADJUVANT CHEMOTHERAPY; BOWEL RESECTION; SURVIVAL; PART; IMPACT;
D O I
10.3802/jgo.2021.32.e42
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: This study investigates the specific morbidity of rectosigmoid resection (RSR) during Visceral-Peritoneal Debulking (VPD) in a consecutive series of patients with stage IIIC-IV ovarian cancer and compares the results of the colo-rectal vs. the gynaecologic oncology team. Methods: All patients with the International Federation of Gynecology and Obstetrics (FIGO) stage IIIC-IV ovarian cancer who had VPD and RSR were included in the study. Between 2009 and 2013 all operations were performed by the gynecologic oncology team alone (group 1). Since 2013 the RSR was performed by the colorectal team together with the gynecologic oncologist (group 2). All pre-operative information and surgical details were compared to exclude significant bias. Intra- and post-operative morbidity events were recorded and compared between groups. Results: One hundred and sixty-two patients had a RSR during VPD, 93 in group 1 and 69 in group 2. Groups were comparable for all pre-operative features other than: albumin (1<2) hemoglobin (2<1) and up-front surgery (1>2). Overall morbidity was 33% vs. 40% (p=0.53), bowel specific morbidity 11.8% vs. 11.5% (p=0.81), anastomotic leak 4.1% vs. 6.1% (p=0.43) and re-operation rate 9.6% vs. 6.1% (p=0.71) in groups 1 and 2, respectively. None of them were significantly different. The rate of bowel diversion was 36.5% in group 1 vs. 46.3% in group 2 (p=0.26). Conclusions: Our study failed to demonstrate any significant difference in the morbidity rate of RSR based on the team performing the surgery. These data warrant further investigation as they are interesting with regards to education, finance, and medico-legal aspects.
引用
收藏
页数:10
相关论文
共 32 条
  • [1] Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis
    Bristow, RE
    Tomacruz, RS
    Armstrong, DK
    Trimble, EL
    Montz, FJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) : 1248 - 1259
  • [2] Impact of Complete Cytoreduction Leaving No Gross Residual Disease Associated with Radical Cytoreductive Surgical Procedures on Survival in Advanced Ovarian Cancer
    Chang, Suk-Joon
    Bristow, Robert E.
    Ryu, Hee-Sug
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (13) : 4059 - 4067
  • [3] Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm
    Chi, Dennis S.
    Eisenhauer, Eric L.
    Zivanovic, Oliver
    Sonoda, Yukio
    Abu-Rustum, Nadeem R.
    Levine, Douglas A.
    Guile, Matthew W.
    Bristow, Robert E.
    Aghajanian, Carol
    Barakat, Richard R.
    [J]. GYNECOLOGIC ONCOLOGY, 2009, 114 (01) : 26 - 31
  • [4] The Clavien-Dindo Classification of Surgical Complications Five-Year Experience
    Clavien, Pierre A.
    Barkun, Jeffrey
    de Oliveira, Michelle L.
    Vauthey, Jean Nicolas
    Dindo, Daniel
    Schulick, Richard D.
    de Santibanes, Eduardo
    Pekolj, Juan
    Slankamenac, Ksenija
    Bassi, Claudio
    Graf, Rolf
    Vonlanthen, Rene
    Padbury, Robert
    Cameron, John L.
    Makuuchi, Masatoshi
    [J]. ANNALS OF SURGERY, 2009, 250 (02) : 187 - 196
  • [5] Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study
    Eisenkop, SM
    Friedman, RL
    Wang, HJ
    [J]. GYNECOLOGIC ONCOLOGY, 1998, 69 (02) : 103 - 108
  • [6] Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Glynne-Jones, R.
    Wyrwicz, L.
    Tiret, E.
    Brown, G.
    Rodel, C.
    Cervantes, A.
    Arnold, D.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 : 22 - 40
  • [7] Bowel anastomoses: The theory, the practice and the evidence base
    Goulder, Frances
    [J]. WORLD JOURNAL OF GASTROINTESTINAL SURGERY, 2012, 4 (09): : 208 - 213
  • [8] The effect of bowel resection on survival in advanced epithelial ovarian cancer
    Jaeger, W
    Ackermann, S
    Kessler, H
    Katalinic, A
    Lang, N
    [J]. GYNECOLOGIC ONCOLOGY, 2001, 83 (02) : 286 - 291
  • [9] Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
    Kehoe, Sean
    Hook, Jane
    Nankivell, Matthew
    Jayson, Gordon C.
    Kitchener, Henry
    Lopes, Tito
    Luesley, David
    Perren, Timothy
    Bannoo, Selina
    Mascarenhas, Monica
    Dobbs, Stephen
    Essapen, Sharadah
    Twigg, Jeremy
    Herod, Jonathan
    McCluggage, Glenn
    Parmar, Mahesh
    Swart, Ann-Marie
    [J]. LANCET, 2015, 386 (9990) : 249 - 257
  • [10] Survival impact of low anterior resection in patients with epithelial ovarian cancer grossly confined to the pelvic cavity: a Korean multicenter study
    Kim, Miseon
    Suh, Dong Hoon
    Park, Jeong-Yeol
    Paik, E. Sun
    Lee, Seungmee
    Eoh, Kyung Jin
    Nam, Joo-Hyun
    Lee, Yoo-Young
    Kim, Jae-Weon
    Kim, Sunghoon
    [J]. JOURNAL OF GYNECOLOGIC ONCOLOGY, 2018, 29 (04)